Document Migration

PRODUCTS

  • The industry’s leading scalable electroporation technology for high-yield, transient expression of complex proteins, vaccines, and biologics.

    • Rapidly transfect from 75 thousand to 20 billion cells
    • High efficiency and cell viability enable flexible media strategies that can deliver significant cost savings
    • Improved yields from transient expression for decreased development timelines
    • Proprietary Flow Electroporation® Technology
    • Faster production of stable clones
    • ISO-certified and CE-marked
  • Clinical trial contracts can be complex, but they don’t have to be. With inSeption Group, you gain a partner that manages every detail of the contracting process with precision and efficiency, so you can stay focused on your study’s success.

  • AES has transformed the landscape of modular cleanroom design, manufacturing and construction. What began as a vision to elevate industry standards has evolved into a legacy of cleanroom solutions that protect the world’s most critical processes.

  • From product development to translation into clinical trials, GTx’s clinically validated scalable electroporation technology is equipped to handle your most complex cellular engineering demands.

    • Rapidly transfect from 75 thousand to 20 billion cells
    • Move forward with 21 CFR Part 11 enabled software
    • Develop quickly with an established regulatory path supported by a FDA Master File
    • Manufacture confidently with closed, cGMP-compliant, ISO-certified and CE-marked products
    • Enjoy MaxCyte’s proprietary Flow Electroporation® technology
  • Accelerate your biomanufacturing capacity with purpose-built modules

    KUBio™ box modular bioprocessing environments are designed to help biopharmaceutical manufacturers bring high-quality biopharmaceuticals to market more quickly. By reducing typical design and construction times and streamlining process execution, they support future expansion and replication needs. Available KUBio™ box modular environments for biosafety levels 1 and 2 (BSL-1 and BSL-2) can be delivered in 10 to 15 months for implementation inside existing infrastructure. The result? Reduced project risk, accelerated delivery of next-gen therapies, and greater flexibility at different production scales and product technologies.

WHITE PAPERS AND CASE STUDIES

NEWS